Holigen Plans to Harvest Two Tons of Cannabis in Sintra

Holigen Holdings Limited, a subsidiary of the Canadian company Flowr, that has a GMP (Good Manufacturing Practices) certified facility in Sintra, announced in a press release that it will harvest approximately 300kg of cannabis flowers in the first quarter of 2022, and is expected to reach a production of around 2 tons this year. Tom Flow, Flowr’s co-founder and Chief Operating Officer (COO), has moved to Portugal to oversee operations and is confident of legalizing adult-use in Portugal.

Holigen is also launching into the EU-GMP co-manufacturing services business, providing services to other producers, including labs, now available to external customers.

“We firmly believe that Holigen’s team and assets are a unique entry point into the European Union. The Sintra facility is one of the few facilities in the European Union (EU) that is GMP certified. If a competitor wants to enter the EU today they will face long regulatory approval times, construction, importing genetics and assembling a quality team with the experience necessary to succeed,” commented Darryl Brooker, Flowr’s CEO. With Tom Flow’s move to Portugal and the partnership with Cookies Creative Consulting and Promotions Inc, Flowr believes Holigen is poised for great success in the near term. “There are several reasons to be in Portugal – the regulatory landscape is changing, the cost structure is highly competitive and there are no real competitors yet in the premium cannabis market.”

Read more about the company Holigen and find other important cannabis news from around the world with the Hemp.im mobile app

Tom Flow on the lookout for the legalization of adult use cannabis in Portugal

Tom Flow, co-founder of Flowr and now Director of Operations in Portugal also made considerations about his move to Portugal: “I have been involved in the planning, construction and operation of several of the world’s leading cannabis facilities and the Sintra facility is without a doubt one of the best facilities in the world for growing premium, high THC cannabis.” But beyond medicinal, Tom Flow is also thinking about the legalization of adult use, which he believes is coming soon: “In Portugal, I see not only a growing market for medicinal cannabis, but discussions around an adult-use regime are also very encouraging. At Holigen, we have built a facility that will be able to cater for a medical cannabis regimen, providing patients with consistent, high-quality products, but we are also looking ahead to when there is an adult-use market. The partnership with Cookies also allows us to be ready for that change.”

Sintra facility is fully operational

According to Flowr, at the Sintra facility, all capital expenditures have been made and the facility is fully operational. Holigen’s medical cannabis facility is about 7,600 square meters with six cultivation rooms, which are now fully operational and producing high THC strains – BC Black Cherry and BC Strawnana. Holigen expects to receive Cookies genetics as early as the first quarter of 2022. Initial in-process testing for both medical cannabis genetics are indicating high THC content levels of over 25% and 27%, respectively.

In addition, Holigen has begun stability and long-term testing on these strains with the goal of having them on the market under its own brand in the second half of 2022. In the meantime, the company is looking for business-to-business or bulk sales of medical cannabis as a way to bring the product to various markets and generate immediate revenue.

Holigen’s Genetics Portfolio

The company has exported its main high-THC strains – BC Pink Kush, BC Black Cherry, and BC Strawnana – from Canada to Portugal, having established a robust stock of healthy mother plants to begin its first harvest. In addition to the Flowr genetics portfolio, Holigen has received import licenses for a wide variety of Cookies genetics, including its well-known Gary Payton, Cereal Milk, Gelatti, Pancakes, and Pink Runtz varieties.

The product registration process and application for ACM (marketing authorization) in Portugal, Germany, and the UK are the next steps, expecting to get approval in the second half of 2022.

Co-manufacturing services

In Portugal, there are several GACP growers, predominantly operating in greenhouses, that require GMP services. After successfully completing validation batches in 2021 and generating approximately 500,000 euros in revenue from “tolling” services last year, the company is now offering these services to additional customers. The tolling services primarily include cutting, drying, curing, and packaging medical cannabis for Holigen’s customers.

Laboratory Services

The Sintra facility has state-of-the-art laboratory equipment, including GC and HPLC diagnostic machines. With the GMP cannabis testing license, Holigen has initiated laboratory services for third parties, providing medical cannabis testing such as cannabinoid potency testing, alphatoxin, and ochratoxin testing, and microbiological testing. Holigen expects that the launch of laboratory services for third parties will also result in significant annual revenue.

__

(Featured image by Jonny_Joka via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in CANNA REPORTER, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.